JP2023551249A - アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物 - Google Patents
アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物 Download PDFInfo
- Publication number
- JP2023551249A JP2023551249A JP2023531700A JP2023531700A JP2023551249A JP 2023551249 A JP2023551249 A JP 2023551249A JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023551249 A JP2023551249 A JP 2023551249A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alzheimer
- compound
- alkylenyl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000087A CU24720B1 (es) | 2020-11-24 | 2020-11-24 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
| CU2020-0087 | 2020-11-24 | ||
| PCT/CU2021/050012 WO2022111742A1 (es) | 2020-11-24 | 2021-11-18 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551249A true JP2023551249A (ja) | 2023-12-07 |
| JP2023551249A5 JP2023551249A5 (cg-RX-API-DMAC7.html) | 2024-11-25 |
Family
ID=80034851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531700A Pending JP2023551249A (ja) | 2020-11-24 | 2021-11-18 | アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299334A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4252749A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118112A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116829137A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021388673A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200071A1 (cg-RX-API-DMAC7.html) |
| CU (1) | CU24720B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006072A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022111742A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008503475A (ja) * | 2004-06-17 | 2008-02-07 | フォーレスト ラボラトリーズ, インコーポレイテッド | メマンチンの放出が改変された製剤 |
| JP2009517420A (ja) * | 2005-11-30 | 2009-04-30 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | ネラメキサン放出調節マトリックス錠 |
| JP2012512247A (ja) * | 2008-12-16 | 2012-05-31 | コドマン・アンド・シャートレフ・インコーポレイテッド | アルツハイマー病の治療における窒素含有クルクミン類似体の利用 |
| JP2016510007A (ja) * | 2013-02-28 | 2016-04-04 | セントロ デ ネウロシエンシアス デ キューバ(ネウロニック) | コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| CN1621039A (zh) | 2003-11-25 | 2005-06-01 | 上海医药工业研究院 | 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂 |
| EP1715843A1 (en) | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| WO2007002497A1 (en) | 2005-06-23 | 2007-01-04 | Envivo Pharmaceuticals, Inc. | Method of treating neurological disorders using clotrimazole and derivatives thereof |
| CU23844B1 (es) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
| CU24583B1 (es) * | 2018-11-06 | 2022-02-04 | Centro De Neurociencias De Cuba | Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) |
-
2020
- 2020-11-24 CU CU2020000087A patent/CU24720B1/es unknown
-
2021
- 2021-11-18 MX MX2023006072A patent/MX2023006072A/es unknown
- 2021-11-18 CN CN202180091389.3A patent/CN116829137A/zh active Pending
- 2021-11-18 AU AU2021388673A patent/AU2021388673A1/en not_active Abandoned
- 2021-11-18 US US18/038,494 patent/US20240299334A1/en active Pending
- 2021-11-18 CA CA3200071A patent/CA3200071A1/en active Pending
- 2021-11-18 KR KR1020237020732A patent/KR20230118112A/ko active Pending
- 2021-11-18 WO PCT/CU2021/050012 patent/WO2022111742A1/es not_active Ceased
- 2021-11-18 EP EP21848149.7A patent/EP4252749A1/en active Pending
- 2021-11-18 JP JP2023531700A patent/JP2023551249A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008503475A (ja) * | 2004-06-17 | 2008-02-07 | フォーレスト ラボラトリーズ, インコーポレイテッド | メマンチンの放出が改変された製剤 |
| JP2009517420A (ja) * | 2005-11-30 | 2009-04-30 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | ネラメキサン放出調節マトリックス錠 |
| JP2012512247A (ja) * | 2008-12-16 | 2012-05-31 | コドマン・アンド・シャートレフ・インコーポレイテッド | アルツハイマー病の治療における窒素含有クルクミン類似体の利用 |
| JP2016510007A (ja) * | 2013-02-28 | 2016-04-04 | セントロ デ ネウロシエンシアス デ キューバ(ネウロニック) | コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230118112A (ko) | 2023-08-10 |
| EP4252749A1 (en) | 2023-10-04 |
| AU2021388673A1 (en) | 2024-03-28 |
| CN116829137A (zh) | 2023-09-29 |
| US20240299334A1 (en) | 2024-09-12 |
| WO2022111742A1 (es) | 2022-06-02 |
| CU20200087A7 (es) | 2022-07-08 |
| WO2022111742A4 (es) | 2022-11-03 |
| CA3200071A1 (en) | 2022-06-02 |
| MX2023006072A (es) | 2023-06-29 |
| CU24720B1 (es) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
| CN1622804A (zh) | 包含阿戈美拉汀的可在口中分散的药物组合物 | |
| JP2019023202A (ja) | Lsd1阻害剤を用いて多発性硬化症を処置する方法 | |
| US9907789B2 (en) | Sustained-release preparation | |
| NZ530289A (en) | Pharmaceutical composition comprising cetirizine and pseudoephedrine that contains less than 5% or no alkalinising agent | |
| JP2016503803A (ja) | 酢酸グラチラマーの経粘膜送達 | |
| CN1173701C (zh) | 含有米氮平的口内崩解组合物 | |
| JPH04210924A (ja) | カルシトニンの経口投与用の製薬組成物及び投薬形態 | |
| CN110996938A (zh) | 雷美替胺的药物组合物及其使用方法 | |
| EP4252749A1 (en) | Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease | |
| HK40092074A (en) | Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease | |
| AU2012241189A1 (en) | Fast Dissolving Solid Dosage Form | |
| JP2014528395A (ja) | 口腔内分散性製剤 | |
| JP2006070027A (ja) | 口腔粘膜投与剤 | |
| KR101124796B1 (ko) | 도네페질 수지 착체 | |
| AU2017261225A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| US20140179712A1 (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
| US20250009698A1 (en) | Nervonic acid-based compositions and methods | |
| ES2383149T3 (es) | Composicion farmacéutica estable para la administración optimizada de un inhibidor de la unión del VIH | |
| WO2025128666A1 (en) | Combination of latrepirdine and a pharmacokinetic stabilizer | |
| Revill et al. | Gabapentin enacarbil | |
| JP2025529123A (ja) | 急性ストレス障害を処置するための方法及び組成物 | |
| WO2026088136A1 (en) | Methods of treating a neurodegenerative disease | |
| US20250152507A1 (en) | Sublingual compositions for erectile dysfunction | |
| US20040082665A1 (en) | Method for treating stress or tension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20230630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260626 |